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Abstract
BACKGROUND
Hypoxia-inducible factor 1α (HIF-1α) is a gene that regulates tumor survival,
neovascularization and invasion. Overexpression of HIF-1α correlates with poor
prognosis in hepatocellular carcinoma (HCC). RO7070179 is a HIF-1α inhibitor
that decreases HIF-1α mRNA and its downstream targets, it could be a potential
treatment in HCC.
AIM
To evaluate safety and preliminary activity of RO7070179 in patients with
previously treated HCC, with focus on a patient with prolonged response to
RO7070179.
METHODS
In the preclinical study of RO7070179 in a HCC xenograft model, the mice were
WJCO https://www.wjgnet.com March 24, 2019 Volume 10 Issue 3149
Informed consent statement: All
study participants, or their legal
guardian, provided informed
written consent prior to study
enrollment.
Conflict-of-interest statement: The
authors declare no potential
conflicts of interest.
Open-Access: This article is an
open-access article which was
selected by an in-house editor and
fully peer-reviewed by external
reviewers. It is distributed in
accordance with the Creative
Commons Attribution Non
Commercial (CC BY-NC 4.0)
license, which permits others to
distribute, remix, adapt, build
upon this work non-commercially,
and license their derivative works
on different terms, provided the
original work is properly cited and
the use is non-commercial. See:
http://creativecommons.org/licen
ses/by-nc/4.0/
Manuscript source: Unsolicited
manuscript
Received: November 8, 2018
Peer-review started: November 10,
2018
First decision: November 14, 2018
Revised: December 17, 2018
Accepted: January 8, 2019
Article in press: January 9, 2019
Published online: March 24, 2019
separated into 4 groups with each group received doses of 0, 3, 10 and 30 mg/kg
for total 10 doses. HCC patients who failed at least one line of systemic treatment,
received RO7070179 as a weekly infusion, each cycle is 6 wk. We evaluated the
safety and HIF-1α mRNA levels of RO7070179.
RESULTS
Preclinical evaluation of RO7070179 in orthotopic HCC xenograft model showed
no significant differences in HCC tumor weight between the 3 and 10 mg/kg
groups. However, dose of 10 mg/kg of RO7070179, has shown 76% reduction of
the amount of HIF-1α mRNA in HCC tissue. In the phase 1b study of RO7070179
in previously treated HCC patients, 8 out of 9 were evaluable: 1 achieved PR and
1 SD. The patient with PR responded after 2 cycles treatments, which has been
maintained for 12 cycles. This patient also showed reduction in perfusion of
dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) after 1 cycle
of treatment. After 1 cycle of treatment, both patients with PR and SD showed
decrease in HIF-1α mRNA at the root of biopsies (each biopsy was divided into 2
specimens, the tip and the root).
CONCLUSION
RO7070179 can reduce HIF-1α mRNA level in HCC patients with SD or PR. It is
well tolerated at 10 mg/kg, with transaminitis as the dose of increased toxicity.
This study indicates that RO7070179 might benefit HCC patients, and an early
signal for clinical benefit can potentially be predicted through changes in either
mRNA level or DCE-MRI within 1 cycle of therapy.
Key words: Hepatocellular carcinoma; Hypoxia-inducible factor 1α; RO7070179, Super-
responder; Dynamic contrast-enhanced-magnetic resonance imaging
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
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INTRODUCTION
Hypoxia-inducible factor 1α (HIF-1α) is a transcription factor that mediates adaptive
responses  to  changes in  tissue oxygenation.  HIF-1α regulates  genes  that  encode
proteins controlling tumor metabolism, pH, neovascularization,  drug resistance,
invasion, autophagy, and cell survival[1-5]. Overexpression of HIF-1α protein has been
found in  multiple  malignant  tumors  including hepatocellular  carcinoma (HCC).
Significant association between HIF-1α overexpression and patient mortality has been
shown in HCC[6]. HCC indicates a strong unmet medical need, as sorafenib had been
the only approved medication for 10 years from 2007-2017[7]. Overexpression of HIF-
1α could be one of the mechanisms for resistance. Targeting HIF-1α can be a useful
approach in HCC.
RO7070179  (EZN-2968)  is  an  antisense  oligonucleotide  targeting  HIF-1α  in  a
synthetic  locked nucleic  acid  form that  are  more  resistant  to  degradation while
maintaining the binding specificity. Previous phase I dose finding studies suggest that
it  is tolerated at a dose of 18 mg/kg IV once a week for three consecutive weeks
followed by 3-wk off in a 6-wk cycle; or up to 13 mg/kg if dosed weekly. The dose
limiting toxicity is hepatotoxicity as manifested by increase of liver function tests
aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT). RO7070179
is accumulated in liver and kidney, and effectively suppresses HIF-1α mRNA level
HIF-1α in post-treatment HCC tumor biopsies. However, a proof of mechanism study
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in patients with various solid tumors leads to an inconsistent result among the down-
regulation of HIF-1α mRNA, HIF-1α protein, mRNAs of several HIF-1α target genes
and tumor perfusion. This study is designed to focus on one single type of tumor
HCC for a reevaluation RO7070179’s target and downstream effectors, based on the
rationale  that  liver  is  one  of  the  organs  with  the  most  abundant  RO7070179
accumulation. Various translational endpoints were designed to study the mechanism
including HIF-1α mRNA levels, protein levels of key HIF-1α targets, angiogenesis,
tumor perfusion and therapeutic efficacy after 1 cycle of treatment with RO7070179.
MATERIALS AND METHODS
Preclinical study design of testing RO7070179 in a HCC xenograft model
Hep3B HCC cells were used to inject orthotopically into the liver of SCID-beige mice.
Without treatment, nearly all mice died in 8 wk. Two weeks after Hep3B tumor cells
were implanted, mice were separated into 4 groups (10 mice for each group) and
received RO7070179 subcutaneous injection at doses of 0, 3, 10 and 30 mg/kg for a
total  of  10  doses  (days  0,  1,  2,  3.5,  7,  10.5,  14,  17.5,  21  and  24.5).  All  mice  were
harvested at 6th weeks after HCC implantation for analysis. Tumor and normal liver
were weighted, and then RNA extracted for examination of HIF-1α mRNA by qRT-
PCR (Taqman) and tissue RO7070179 oligo levels. Other analysis of the liver and
tumor specimens include genome-wide microarrays, proteins with IHC, angiogenesis
with CD31 staining, Ki67, tumor apoptosis marker Casp-3.
Analysis of the HIF1α mRNA
The AllPrep DNA/RNA/miRNA universal kits were used for preparation of RNA.
First,  250  ng  of  total  RNA  was  prepped  using  the  high  capacity  cDNA  reverse
transcription kit (Life Technologies) and final product normalized to 100 µL. Among
them,  4  µL  was  used  for  qPCR  by  the  TaqMan  gene  expression  assay  (Life
Technologies) specific to HIF1α transcripts and a panel of 4 endogenous controls
(GAPDH, UBE2D2, SFRS4 and CTBP1). To analyze the relative expression level of
HIF-1α, the mean Ct value (Ct - cycle threshold, is a DNA quantification measurement
in real time PCR that contains the number of cycles where the fluorescence surpasses
the threshold of background level) of each gene expression assay was determined
from 3 replicates. The linear range of Ct values was determined by the validation
method. Delta Ct of HIF1α and the geometric mean of endogenous controls were
calculated. The Delta Ct of each specimen and a Universal Human Reference RNA
(UHRR) were used to determine the relative expression level of HIF-1α (Delta Ct) of
each specimen.
Immunohistochemistry analysis
Immunohistochemistry (IHC) was performed per standard procedures using the
following antibodies; HIF-1α (Cat#LS-C177574, from LS Bio); HIF-2α (#PA1-16510,
Thermo);  VEGF (#ab52917,  Abcam);  CD31 (#ab28364,  Abcam);  Ki67 (#VP-RM04,
Vector); cleaved Caspase 3-Asp175 (#9664s, Cell Signaling).
Analysis of the RO7070179 oligo levels
The quantification of the oligo levels of RO7070179 is conducted with a hybridization-
ELISA  procedure  for  the  determination  of  RO7070179.  The  method  involves
hybridization  of  the  antisense  oligonucleotide  (containing  phosphorothioate
modifications in its backbone and LNA modification to some of its sugar moieties) to
complementary oligonucleotide probes, one (capture probe) complementary to the 5’-
half of the RO7070179 molecule, and one detection probe complementary to the 3’-
half of the molecule. The capture probe is conjugated with biotin which mediates non-
covalently binding to the surface of a Reacti-Bind Neutravidin coated black plate,
whereas the detection probe is conjugated with digoxygenin. Measurement of the
surface  bound analyte  is  accomplished by the  addition  of  a  Fab-fragment  of  an
antibody directed against digoxigenin. This Fab-fragment is coupled to an alkaline
phosphatase which converts AttoPhos® to a fluorescent product that is directly related
to the amount of bound RO7070179.
Clinical study for the proof of mechanism
A phase 1b clinical trial was also conducted in 6 sites. Patients with advanced HCC
who fulfill the criteria of HCC diagnosis according to the American Association for
the Study of Liver Disease criteria and have failed at least one line of systemic therapy
were enrolled. Other key eligibility criteria include Child-Pugh score A, ECOG 0-1,
adequate organ function with liver function AST/ALT no higher than 3 X upper limit
of normal (ULN) and platelet above 60000/µL, bilirubin and creatinine no higher than
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2 X ULN. RO7070179 was administered as a 2-h weekly IV infusion in 6-wk cycles
after two loading doses of 13 mg/kg RO7070179 administered on Days 1 and 4 in
Week 1 of Cycle 1. If unacceptable toxicities were observed in 30% of existing patients,
subsequent patients would have a dose reduction to 10 mg/kg weekly or 6 mg/kg if
still not tolerable.
Extensive translational analyses were included in for the study. All patients should
have  a  dynamic  contrast-enhanced  magnetic  resonance  imaging  (DCE-MRI)  to
analyze the tumor perfusion in baseline and 1 cycle after treatment to evaluate tumor
perfusion using Ktrans and other parameters. The result of DCE-MRI is used to select a
region in tumor for biopsy in baseline. The region selected correlates to no evidence of
necrosis and relatively lower blood flow, hence potentially higher HIF-1α expression.
Patients  also  had a  second biopsy after  1  cycle  of  treatment  at  the  same site  for
comparison.  Clinical  efficacy  was  assessed  by  contrast  CT  every  3  mo  until
progression or death. The biopsy was targeted to have a core of 20 mm in length, with
tips  of  both ends saved in  cryovials  for  RNA extraction,  and the  next  6  mm for
fixation  in  10%  formalin  for  histology  examination  and  IHC.  The  remaining
specimens were snap frozen for measuring of drug levels as part of the tumor PK
analysis.
RESULTS
Preclinical evaluation of the RO7070179 in orthotopic HCC xenograft model
Four groups of mice were treated with RO7070179 at the doses of 0, 3,  10 and 30
mg/kg for total  10 doses.  Mice in the group that received the highest dose at  30
mg/kg/dose failed to tolerate treatment with 2 deaths at day 6, 2 deaths at day 7 and
3 deaths at day 8. The remaining 3 mice of this group were then sacrificed ahead of
schedule on day 9. The liver enzymes AST/ALT/ALP (alkaline phosphatase) of these
3 mice all showed significant elevation above 800, consistent with hepatotoxicity from
the study medication. Mice in the remaining 3 groups were sacrificed at the scheduled
time at 1 cycle. AST/ALT in blood of mice receiving 3 and 10 mg/kg RO7070179 also
revealed a dose-dependent increase, consistent with RO7070179-related liver toxicity.
Liver in the three remaining groups were dissected first and compared in weights.
The weights  of  the  control  and those  receiving 3  mg/kg RO7070179 showed no
difference, but that receiving 10 mg/kg had a statistical increase compared with the
other two groups, which is potentially related to a compensatory proliferation due to
hepatotoxicity. Liver tumors were then dissected and weighted, and no statistical
difference was observed.
Pharmacokinetics of the RO7070719
Concentrations of RO7070719 in plasma, tumor and healthy liver followed dose-linear
kinetics over this dose range. The mean accumulated liver concentrations were 9.92,
27.1 and 66.6 µg/g tissue at the 3, 10, and 30 mg/kg/administration, respectively
(Figure 1A). The mean concentration in tumors was 2.38 and 11.5 µg/g tissue at 3.0
and  10.0  mg/kg/administration,  respectively,  indicating  that  tumors  were  less
exposed to RO7070719 than normal liver tissue (Figure 1B).
Down-regulation of HIF-1α mRNA and its downstream effectors after RO7070179
treatment
Based  on  the  TaqMan  qPCR  analysis  of  HIF-1α  mRNA  (the  primary  target  of
RO7070179) in normal liver, the groups received 3 and 10 mg/kg achieved 82% and
84%, decreases in the HIF1α mRNA level when compared to that of the control group
(Figure 1C). When compared to control in the orthotopic tumor the levels of HIF-1α
mRNA showed a 53% decrease in the group of 3 mg/kg compared to control, and a
76% of decrease in the group of 10 mg/kg (Figure 1D). This result support the target
engagement of RO7070179 in both normal liver and orthotopic tumor, and normal
liver is more sensitive to RO7070179 than the orthotopic tumor.
Downstream effector of HIF-1α mRNA
Immunohistochemical analysis was conducted in tumor to examine the protein levels
of HIF-1α and its downstream effector VEGF, apoptosis marker activated Caspase 3 as
shown in Figure 2. The levels of HIF-1α showed a barely visible decrease in protein
level in the group receiving 3 mg/kg RO7070179, and an obvious decrease in the
group receiving 10 mg/kg RO7070179, which is consistent with the HIF-1α mRNA
decrease of 53% and 76%, respectively. Similarly, minimal change was noticed in the
levels of VEGF and activated Caspase 3 in the tumor treated with 3 mg/kg; whereas
an obvious decrease in VEGF and an increase of activated Caspase 3 were observed in
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Figure 1
Figure 1  Concentrations of RO7070719 in normal mouse liver, Hep3B orthotopic tumor and specimens harvested at Day 39. A: Concentrations of
RO7070719 in normal liver; B, C: Hep3B tumor xenograft and the levels of HIF-1α mRNA in (C) normal liver; D: Hep3B tumor xenograft. Normal mouse liver (A) and
Hep3B orthotopic tumor (B) specimens harvested at Day 39 (n = 10/group, except at 30 mg/kg n = 3/group harvested at Day 23) were quantified using hybridization-
ELISA for RO7070719 concentrations. The levels of HIF-1a mRNA were quantified by qPCR in normal liver (C), and Hep3B orthotopic tumor xenografts (D).
tumors treated with 10 mg/kg, which is consistent with those of the HIF-1α mRNA.
These results indicate that the biological effect of HIF-1α decrease can be further
extended to VEGF and eventually to an induction of caspase cascade. We created the
biomarker  analysis  flow  chart  to  illustrate  the  mechanism  of  action  of  HIF-1α
inhibitors in HCC (Figure 3)[8].
The positive animal study prompted a clinical trial to investigate the activity of
RO7070179 in HCC patients who have failed at least one line of systemic therapy,
predominately sorafenib. A total of 9 male patients were enrolled in the study with
age group between 45 to 75 years. Three of 8 patients (37.5%) were below 65 years and
the remaining 5 patients (62.5%) were more than 65 years, the median age was 69
years. Two of 8 patients (25.0%) were Asian, 3 of 8 patients (37.5%) were Black or
African American and 3 of 8 patients (37.5%) were white. Two of 8 patients (25.0%)
were from Hispanic or Latino origin, while six of 8 patients (75.0%) were from non-
Hispanic or Latino origin. The median weight (kg) of patients at baseline was 71.95.
The minimum and maximum weight of patients enrolled for study was 56.7 and 111.3
respectively. The median height (cm) of patients at baseline was 170. The minimum
and maximum height of patients enrolled for study was 161 and 179 respectively. The
median BMI (kg/m2) of patients at baseline was 26.68. The minimum and maximum
BMI (kg/m2) of patients enrolled for study was 19.2 and 39.9 respectively.
Side effects
The study started with a dose at 13 mg/kg IV at days 1 and 4 in week 1 for loading,
followed by  13  mg/kg  weekly  afterwards.  The  dose  was  reduced  to  10  mg/kg
afterwards due to observation of increased toxicity in 3 of the first 6 patients. The
toxicity of RO7070179 was considered related to drug accumulation in liver, and HCC
patients have less liver reserve compared to those with other malignancies tested in
prior phase I studies. Subsequently dose was reduced to 10 mg/kg weekly and it was
well tolerated in the next 3 patients.
The most common adverse events (AEs) were ALT increased (5 patients, 55.6%),
AST increased (5 patients,  55.6%),  blood creatinine increased (4 patients,  44.4%),
fatigue (4 patients, 44.4%), chills (3 patients, 33.3%) and decreased appetite (3 patients,
33.3%). The most common grade 3 or 4 AEs were ALT increased (4 patients, 44.4%)
and AST increased (4 patients, 44.4%).
Efficacy
Only 3 of the 9 patients were able to complete 2 cycles of treatments and had efficacy
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Figure 2
Figure 2  Immunohistochemistry analysis. Immunohistochemistry analysis of the control mouse xenograft, tumor xenograft treated with 3 mg/kg RO7070179, which
exhibited 53% decrease in hypoxia-inducible factor 1α (HIF-1α) mRNA, and the tumor xenograft treated with 10 mg/kg RO7070719, which exhibited 76% decrease in
HIF-1α mRNA. HIF-1α: Hypoxia-inducible factor 1α; VEGF: Vascular epidermal growth factor.
evaluation by a follow-up CT scan (Figure 4). One patient, who had a prior surgical
resection and recurred in the surgical margin with metastatic to lung, had a robust
efficacy. The pretreatment liver lesion was as large as 6.7 cm in size with multiple
lung metastasis. With 2 cycles of treatments, this patient achieved PR by mRECIST
criteria, and the lesion in liver decreased to 3.7 cm along with reduction in size and
number of lung lesions. As of today, this patient has completed the study (12 cycles)
and  stayed  in  PR  as  of  May  14,  2018  of  CT  scan.  The  lung  lesions  complete
disappeared and liver lesion down to 2.3 cm without contrast enhancement. Two
other patients also completed 2 and 4 cycles, respectively. One had SD and one with
PD at the first assessment post cycle 2.
Biomarker analysis of the super-responder
The  mRNA of  HIF-1α  was  first  examined by  qPCR.  Specimens  1  are  the  tumor
specimens located at the tip of the biopsy cores and specimens 2 are those at the other
end of biopsy, called root so that different locations of biopsies can be investigated to
detect  any  potential  spatial  heterogeneity.  The  results  are  shown  in  Table  2.
Unfortunately, no definitive trend can be detected for either specimens 1 or 2, or
before  and after  RO7070179 treatment.  This  suggests  a  significant  temporal  and
spatial relationship exist in tumor.
As of safety cut-off date, 28 Feb 2017, efficacy data is represented as “spaghetti
plots” for HIF-1α in specimens obtained prior to the administration (screening) of the
HIF-1α inhibitor and after cycle 1 of (6 wk) treatment.  Dots represent individual
specimens; lines connect specimens from individual patients taken at consecutive time
interval.  Expression is  shown as  the difference in  the cycle  threshold (Ct)  value
between the HIF-1α gene and the mean Ct of  the reference genes,  higher values
correspond to stronger expression.
Table 2 shows gene expression as delta Ct value of specimen 01 in patient. The
super-responder patient was observed with lower delta Ct value as compared at
screening  corresponding  to  up  regulation  expression  of  gene  as  compared  at
screening. It showed down regulation of HIF-1α gene.
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Figure 3
Figure 3  Biomarker analysis plan to dissect mechanism of action of hypoxia inducible factor-1αlpha
inhibitors. HIF-1α: Hypoxia inducible factor-1αlpha; HIF2: Hypoxia inducible factor 2; HIF-1α mRNA: Hypoxia
inducible factor 1-alpha messenger ribonucleic acid; EPO: Erythropoietin; VEGF: Vascular epidermal growth factor;
IHC: Immunohistochemistry; vWF: Von willebrand factor; CD34: Cluster of differentiation 34; PR: Partial response;
DCE-MRI: Dynamic contrast-enhanced magnetic resonance imaging; RECIST: Response evaluation criteria in solid
tumors.
Analysis of tumor perfusion by DCE-MRI
The DEC-MRI  scans  of  the  patient  who achieved durable  PR were  examined in
details. Figure 5 shows the heat map of the perfusion scan in liver and tumor before
(Figure 5A) and after the first cycle of treatment (Figure 5B), and a clear reduction was
demonstrated after treatment. The Ktrans,  a parameter representing perfusion, was
calculated in tumor as shown in Table 3.
DISCUSSION
Preclinical study
High level of HIF-1α mRNA indicates poor prognosis in HCC[9,10]. During hypoxia,
HIF-1α does not go through degradation by enzyme prolyl hydroxylase, instead it is
stabilized and accumulated in the nucleus. HIF-1α then activates the transcription of
target  genes such as  vascular  endothelial  growth factor  (VEGF) that  contributes
angiogenesis.  In  addition,  it  stimulates  transcriptions  of  growth factors  such as
insulin-like  growth  factor-2  and  transforming  growth  factor-α  that  lead  to  cell
proliferation.  It  also  induces  epithelial-mesenchymal  transition  by  inhibiting  E-
Cadherin, which maintains the epithelial integrity, thus stimulates tumor invasion.
HIF-1α therefore leads to neovascularization, proliferation, and metastasis in various
tumors, including HCC[11]. RO7070179, a HIF-1α inhibitor has been studied in HCC
xenograft models and later on in HCC patients.
Liver toxicity is dose dependent
In the orthotopic HCC mice model, the absorption of RO7070179 is higher in normal
liver compared to HCC tissue. Therefore, after treatment with RO7070179, the level of
HIF-1α mRNA (the target of RO7070179 inhibition) is lower in normal liver than in
HCC. In order to achieve adequate reduction of HIF-1α protein or mRNA level in
HCC, a high dose of RO7070179 is required. This was illustrated in the preclinical
study using orthotopic  HCC xenograft  mice.  The groups that  received 3  and 10
mg/kg exhibited dose dependent-increase of AST/ALT level, while the highest dose
of  30  mg/kg led to  liver  toxicity  (7  out  of  10  mice  died,  and the  remaining had
excessively high level of the AST/ALT beyond 800).
No  difference  in  HCC  tumor  weights  were  shown  between  the  two  groups,
indicating  that  the  lower  dose  (3  mg/kg)  had  produced  similar  tumor  volume
reduction compared to the higher dose (10 mg/kg). Liver toxicities were explained by
the pharmacokinetics (PK) data, which showed that RO7070179 achieved a higher
concentration in normal liver than the tumor, in a dose dependent manner.
Downstream targets indicate that 10 mg/kg is the optimal dose of RO7070179
At a dose of 10 mg/kg, RO7070179 decreased the level of HIF-1α mRNA by 76%,
which was sufficient to reduce the protein level of HIF-1α and the downstream target
VEGF of HIF-1α and induction of apoptosis (shown by activated caspase 3) (Figure 2).
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Figure 4
Figure 4  CT scans of patient who achieved partial response before and after treatment. Tumor in liver is circled by arrowheads. The size of tumor was 6.7 cm
before treatment, and decreased to 3.7 cm after 4 mo of treatment, and 2.3 cm after 8 mo of treatment.
However, at the dose of 3 mg/kg, RO7070179 was able to reduce mRNA level by 53%,
but HIF-1α protein level did not change, nor was the downstream target of HIF-1α
mRNA (VEGF) or apoptosis based on activated caspase 3. These findings suggest that
it  is  necessary to suppress at  least  75% of the mRNA level  of  HIF-1α in order to
accomplish adequate inhibition of HCC tumor clinically.
Phase 1b study
In our phase 1b study of RO7070179 in previously treated HCC patients, the primary
end point of HIF-1α mRNA level change after 1 cycle of treatment was not met, and
the study was terminated early. The secondary end point of this study regarding the
safety, efficacy, and pharmacokinetics of RO7070179 could not be done due to the
small number of patient enrolled. However, the extra-ordinary response observed in
one single patient warrant us to undergo detailed investigation of this this patient to
learn  any  lesion  from  this  patient.  We  will  focus  our  discussion  on  the  super-
responder.
Super-responder
DCE-MRI changes correlate with response: This super-responder achieved PR after 2
cycles of treatment (Figure 5) and this response is still maintained after 12 cycles. The
response indicates that RO7070179 induces a rapid response as early as 2 cycles which
can be potentially long lasting. In consistent with the MRI tumor shrinkage, Ktrans in
DCE-MRI also exhibit a significant decrease after 1 cycle treatment (Table 3). This
indicated that the reduction of tissue perfusion in the tumor after 1 cycle of treatment
reflected true decrease in tissue perfusion, as liver background perfusion did not
change from the baseline. Reduction in tissue perfusion on DCE-MRI correlates with
an early response to therapy.
Tissue perfusion and permeability correlate with PFS
In a prospective study of  31 HCC patients who were treated with sorafenib and
tegafur/uracil,  the progression free  survival  (PFS)  was 29.1  wk in patients  with
reduction of Ktrans  ≥ 40% vs  8.7 wk in patients with reduction of Ktrans  < 40%. This
change was demonstrated as early as 14 d on treatment[12]. The overall survival (OS) is
also longer in patients with Ktrans ≥ 40% compared to patients with Ktrans < 40% (53 wk
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Table 2  Fold of changes in hypoxia inducible factor-1αlpha mRNA by qPCR
Number Patient ID Specimen 1 at tip site(fold changed) Specimen 2 at root site(fold changed)
11 2886230004 (super-responder) 1 0.91 0.191
Specimen 1 is the tip of the biopsy, and specimen 2 is the other end of biopsy. A difference in the number of cycles was assumed to be a 2-fold difference.
1The results of the patient who had a robust clinical response in partial response.
vs 14.9 wk, respectively)[12]. Even though the patient with PR has not reached PFS as of
January 27, 2018 (18 mo), our study is consistent with previously published literature
that Ktrans ≥ 40% (Table 3) can lead to longer PFS.
Root of the biopsy demonstrates mRNA level changes
In the super-responder patient with PR, HIF-1α mRNA levels both decreased after 1
cycle of treatment. Interestingly, this change was much more pronounced in specimen
2. We attribute this to tumor heterogeneity as different part of tumor could have
spatial and temporal variation in tumor blood perfusion, resulting in different levels
of HIF-1α. This explains the usage of tumor biopsy for analysis of HIF-1α mRNA or
protein levels is not reliable and poorly correlated with the clinical outcome. Similar
variation in HIF-1α mRNA was observed in other patients. For example in the patient
who achieved SD, specimen 1 was high after 1 cycle treatment, while specimen 2 is
lower than specimen 1. Both patients with PR and SD showed decrease of the HIF-1α
mRNA after  1  cycle  treatment  at  specimen  2.  On  the  other  hands,  patient  with
progression of disease (PD) showed increase level of HIF-1α mRNA at specimen 2.
Effects on HIF-1α mRNA and protein level vary by mechanism of action of HIF-1α
inhibitors
Each HIF-1α inhibitor has a slight different mechanism of action. For instance, PX-478
works in transcriptional and translation level, causes reduction both in HIF-1α mRNA
and protein level[13]. Other HIF-1α inhibitors only decrease the HIF-1α mRNA level
such as GL331[14]. It works by inhibiting the target genes such as VEGF. RO7070179, an
antisense oligonucleotide that also only decrease HIF-1α mRNA level with minimal
effect on HIF-1α protein level. HIF-1α inhibitors can cause target gene downstream
changes  by  inhibiting  the  tumor-induced  angiogenesis,  regardless  if  there  is  a
decrease in HIF-1α mRNA alone or in both mRNA and protein level[15,16]. This also
illustrates the difficulty in using HIF-1α mRNA or protein as the biomarkers for
clinical prediction.
RO7070179  achieved  PR  in  1  out  of  9  HCC  patients,  an  early  response  can
potentially be predicted through either mRNA level change or reduction in tissue
perfusion  on  DCE-MRI  within  1  cycle  of  therapy  using  the  root  of  the  biopsy
specimen.
HIF-1α promotes tumor survival, neovascularization and tumor invasion especially
in HCC. RO7070179 is an HIF-1α inhibitor that is well tolerated at 10 mg/kg, with
transaminitis  as  the  dose  limiting toxicities.  It  reduces  HIF-1α mRNA level  and
downstream targets, it could be a potential treatment in HCC. In a super-responder
HCC patient, HIF-1α mRNA level decreased at both specimen 1 (tip of biopsy) and
specimen 2  (root  of  biopsy)  after  1  cycle  (6  wk)  of  RO7070179 treatment.  It  also
showed an early signal response from DCE MRI analysis by decrease of perfusion in
HCC  tumor  after  1  cycle  of  treatment.  In  a  super-responder  HCC  patient  who
achieved  PR  response  at  2  cycle  (12  wk),  continued  until  12  cycles.  This  study
indicates  that  RO7070179  might  benefit  HCC  patients  and  its  response  can  be
predicted through early 6 wk of  DCE MRI and biopsy of  tumor.  This result  will
require more patients for validation.
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Table 3  The difference in Ktrans for the tumor and the liver between pre and post-treatment
Pre-treatment Post-treatment
Tumor
Ktrans pre-treatment: 849 × 10-3/min Ktrans post-treatment: 122 × 10-3/min
Liver (left lobe)
Ktrans pre-treatment: 245 × 10-3/min Ktrans post-treatment: 255 × 10-3/min
Ktrans is a measurement in dynamic contrast-enhanced magnetic resonance imaging to determine tissue perfusion and permeability. After 1 cycle of
treatment, Ktrans in the patient with PR demonstrated decrease from baseline (Table 3) in the tumor, while Ktrans in the liver remained stable during the 2
time period.
Figure 5
Figure 5  The effect of RO7070179 in the super responder using heat maps (red means more perfusion and green means less perfusion) between the 2 time
periods (baseline 6/20/16 and after 1 cycle 7/28/16). The change of color from red to green correlates with decrease in perfusion between those time periods. A:
Pretreatment heat map from pretreatment perfusion magnetic resonance imaging (MRI) (Coronal Section); B: Post treatment heat map from posttreatment perfusion
MRI (Coronal Section to include aorta which was used as internal standard for blood flow calibration).
ARTICLE HIGHLIGHTS
Research background
Hypoxia-inducible factor 1α (HIF-1α) is a gene that regulates tumor survival, neovascularization
and invasion.  Overexpression  of  HIF-1α  correlates  with  poor  prognosis  in  hepatocellular
carcinoma (HCC).  RO7070179 is  an HIF-1α inhibitor  that  decreases  HIF-1α mRNA and its
downstream targets, it could be a potential treatment in HCC.
Research motivation
HIF-1α inhibitor such as RO7070179 has a potential  benefit  for HCC patients in the future.
Eventhough, in this study there was only one super-responder HCC patients that showed PR
with RO7070179. It needs validation in a large population and studies.
Research objectives
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The purpose of this study is to evaluate safety and preliminary activity of RO7070179 in patients
with previously treated HCC, with focus on a patient with prolonged response to RO7070179.
Research methods
The research methods  is  a  prospective  study in  preclinical  study of  RO7070179  in  a  HCC
xenograft model, the mice were separated into 4 groups with each group received doses of 0, 3,
10 and 30 mg/kg for  total  10 doses.  HCC patients  who failed at  least  one line of  systemic
treatment, received RO7070179 as a weekly infusion, each cycle is 6 wk. We evaluated the safety
and HIF-1α mRNA levels of RO7070179.
Research results
Preclinical evaluation of RO7070179 in orthotopic HCC xenograft model showed no significant
differences in HCC tumor weight between the 3 and 10 mg/kg groups. However, dose of 10
mg/kg of RO7070179, has shown 76% reduction of the amount of HIF-1α mRNA in HCC tissue.
In  the  phase  1b  study  of  RO7070179  in  previously  treated  HCC patients,  8  out  of  9  were
evaluable: 1 achieved PR and 1 SD. The patient with PR responded after 2 cycles treatments,
which has been maintained for 12 cycles. This patient also showed reduction in perfusion of
DCE-MRI after 1 cycle of treatment. After 1 cycle of treatment, both patients with PR and SD
showed decrease in HIF-1α mRNA at the root of  biopsies (each biopsy was divided into 2
specimens, the tip and the root).
Research conclusions
RO7070179 can reduce HIF-1α mRNA level in HCC patients with SD or PR. It is well tolerated at
10  mg/kg,  with  transaminitis  as  the  dose  of  increased  toxicity.  This  study  indicates  that
RO7070179 might benefit HCC patients, and an early signal for clinical benefit can potentially be
predicted through changes in either mRNA level or DCE-MRI within 1 cycle of therapy.
Research perspectives
RO7070179 has shown encouraging activity in previously treated HCC patients, however such
activity needs to be further evaluated in a phase II study with more patients.
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